SNTI
Senti Biosciences Holdings, Inc.Company with tickers: SNTI
CIK
1854270
CUSIP
81726A209
Shares Outstanding
31,144,754
Website
https://www.sentibio.com
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $16,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $4,632,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $5,281,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-4,616,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-4,221,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Reportable Segment | $2,561,000 | $0 | $22,000 |